StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
VAXXA.ST$0.54+9.76%
Fair $0.54+0.0%

VAXXA.ST

VAXXA.ST

Technology / Software - ApplicationStockholm

$0.54

+0.05 (+9.76%)

Fairly Valued+0.0%Fair Value $0.54Fund rank 26/100 · Data gapFallback financials|
SA 15/F
F-Score: 3/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $-2.4M · quality 46.3/100

Data gap 26/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 15/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

15/100

F

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -62.3%, below the 5% threshold
Thesis & Journal · VAXXA.STLocal privado en este navegador · VAXXA.ST
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$23M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-62.3%

↓

Gross Margin

11.3%

↓

Debt/Equity

0.02

↓
52-Week Range$1
$0$1

TradingView lightweight chart

VAXXA.ST price, volumen y niveles de valoración

Último $0.540Periodo -99.7%
Fair value: $0.540

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

—

FCF margin

3.2%

FCF / Net income

-0.26x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $75.0M · net income $-9.4M · FCF $2.4M

2022-FY → 2025-FY

Gross margin

11.3%— pts

Operating margin

-12.5%— pts

Net margin

-12.5%— pts

FCF margin

3.2%— pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$75.0M$75.0M$81.7M$54.9M—
Net Income$-9.4M$-9.4M$388000.00$-5.1M$-41.9M
EBITDA$-7.0M$-7.0M$2.6M$-3.2M$-41.7M
EPS-0.22-0.220.01-0.22-5.68
Gross Margin11.3%11.3%13.9%10.7%—
Operating Margin-12.5%-12.5%0.4%-7.9%—
Net Margin-12.5%-12.5%0.5%-9.3%—
Balance Sheet
Debt/Equity0.020.020.020.04—
Current Ratio1.131.13———
Cash Flow
Free Cash Flow$2.4M$2.4M$-3.4M$-2.4M$-23.4M
Returns
ROE-62.3%-62.3%2.0%-50.7%-298.0%
Valuation
P/E——117.05——
EV/EBITDA——13.72——
P/B1.561.562.302.520.95
Growth & Yield
Revenue Growth-8.1%-8.1%48.7%——
EPS Growth-2169.4%-2169.4%104.7%96.1%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -48.3%

Total return

-48.3%

Start / end P/E

n/dx → n/dx

EPS bridge

0.01 → -0.22

Residual

-48.3%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-48.3%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.